

Nurse AdviseERR®

Educating the Healthcare Community About Safe Medication Practices

Practitioners need to warn patients about purchasing counterfeit drugs online

Practitioners should be prepared for patients who may present to different healthcare settings with adverse reactions after knowingly or unknowingly taking substandard and falsified (SF) drugs. SF drugs are counterfeit or fake drugs made to resemble genuine pharmaceutical manufacturers' medications. We warned of this growing threat to patient safety in our acute care newsletter, in the May 16, 2024 article, *ISMP urges increased action at the practice level to halt the growing danger of counterfeit drugs*, and again in the April 10, 2025 article, *Implement strategies to prevent persistent medication errors and hazards: 2025*. We are concerned that not all practitioners recognize this risk, and we urge organizations to implement measures to proactively educate patients about illegal, so-called "online pharmacies" and websites selling drugs at discounted prices. Below is a recent case reported to ISMP. While reading about this event, look for indicators that the product was not genuine and consider what changes could be implemented within your organization to protect patients from being harmed by SF drugs.

Error Reported to ISMP

A patient presented to the emergency department (ED) with uncontrolled nausea and vomiting after injecting what was presumed to be a 10 mg dose of semaglutide, rather than the intended 0.5 mg dose. The prescriber ordered intravenous (IV) 0.9% sodium chloride, metoclopramide, and ondansetron, which a nurse administered to the patient. The ED physician discharged the patient 24 hours later with prescriptions for anti-emetics to treat the persistent side effects.

The patient told the ED staff that their provider had prescribed **WEGOVY** (semaglutide) for obesity. They could not afford the medication copay. So, the patient purchased what they thought was semaglutide for \$500 through an internet website (the website was not shared with ISMP). The patient was not provided with education on how to prepare or administer the dose.

When the product arrived, the United States Postal Service (USPS) label indicated it came from a residential address. The "medication" came in a cardboard box without prescribing information or patient-specific instructions. It contained "sterile water" in unlabeled glass ampules (Figure 1). The patient was also only provided with 50-unit insulin syringes. The box included a carton of 10 vials with labels indicating each vial contained 10 mg semaglutide sterile lyophilized powder (Figure 2). The vial labels had a lot number (ZPHC768) and an expiration date (3/2027) but did not contain a national drug code (NDC) or any type of drug identification number.



Figure 1. The "sterile water" diluent came in unlabeled glass ampules, without a filter needle to withdraw the contents.




Figure 2. The vials (one example shown to the left) were labeled as "Semaglutide Sterile Lyophilized Powder" and "10 mg/vial," and there was a lot number and expiration date on the label (right) but no NDC.

SAFETYwires

Cap color led to close call with high-alert medications. A certified registered nurse anesthetist (CRNA) found vials of phenylephrine 10 mg/mL in the pocket designated for dexmedetomidine 200 mcg/2 mL vials (Figure 1) in an open



Figure 1. Dexmedetomidine (left) and phenylephrine (right) vials were found mixed together in the dexmedetomidine pocket in an open matrix drawer.

matrix drawer of an anesthesia tray. The dexmedetomidine (used for sedation) vials (by Piramal Critical Care) and phenylephrine (used to treat hypotension) vials (by Avet) are similar in size and have similar color caps (pink) (Figure 2). While the color of medication vial caps should



Figure 2. Dexmedetomidine (left) and phenylephrine (right) vial caps are the same pink color.

not be relied on alone, the pharmacy had previously purchased these products from other manufacturers with different color

continued on page 2 — Counterfeit drugs >

continued on page 2 — SAFETYwires >

> **Counterfeit drugs** — continued from page 1

The carton label stated that the product was “Produced by SecureSemaglutide Labs” and that it was “SWISS MADE” and had a “GMP” seal indicating it was manufactured in a good manufacturing practice facility (**Figure 3**). Although semaglutide approved for use in the United States is intended for subcutaneous injection only, the carton stated, “To Be Injected Subcutaneous or Intramuscular.”

The carton’s side panel had instructions to mix 1 mL of “sterile water” into the “vail” (i.e., vial) and that the initial dose is 0.5 mg injected subcutaneously once weekly, with titration information (**Figure 4**).

The instructions did not specify the volume the patient should administer for the dose. However, if the vial contains 10 mg of drug and if the patient is to dilute it with 1 mL of sterile water (10 mg/1 mL), then the initial dose would be 0.5 mg/0.05 mL. From what the ED staff understood, the patient administered a full 10 mg vial (1 mL) using two 50-unit (0.5 mL) insulin syringes.




Figure 3. The carton label indicated the product is “Produced by SecureSemaglutide Labs,” “SWISS MADE,” with a “GMP” seal, and that it is “To Be Injected Subcutaneous or Intramuscular.”




Figure 4. The instructions lack information about the volume needed to administer a dose.

Potential Red Flags

While some issues may be more noticeable to healthcare practitioners than patients, there were several clues that something was not right:

- The drug was purchased without a prescription online “from Switzerland”
- The patient was not provided with education, and no pharmacist was available for counseling
- The medication was shipped with a United States residential return address label
- There was no contact information (i.e., phone number) for follow-up questions
- There was no patient-specific label or instructions about what volume to administer
- The patient was sent insulin syringes without instructions on what marking on the syringe to use to prepare a dose
- Vial was misspelled on the product labels (e.g., “via” on the vial, “vail” on the carton)
- A trailing zero (e.g., 2.0 mg) was used on the carton label when indicating the dose increase
- The “sterile water” ampules did not contain a label

continued on page 3 — **Counterfeit drugs** >

> **SAFETYwires** continued from page 1

caps. Years before, the CRNA had treated a patient who had inadvertently received 10 mg of phenylephrine intravenous (IV) push resulting in irreversible brainstem damage, so they appreciated the severity of harm if these high-alert medications were mixed up.

Manufacturers’ product labels (and vial caps) might change in color, so that should not be used to identify any medication. This speaks to the importance of reading the product label three times (when obtaining the item, just prior to use, and when discarding it or returning it to stock). To prevent misidentifying medications by viewing only the vial caps, avoid storing vials in an upright position, especially when stored in a bin or drawer below eye level. Store them in a way that always keeps their labels visible. Maximize the use of locked-lidded pockets and do not use open matrix drawers to store high-alert medications or drugs with look-alike packaging. In addition, utilizing barcode scanning when refilling cabinets and prior to medication administration is an important error prevention strategy.

When the pharmacy receives a new product, conduct a proactive review of product characteristics that might cause confusion and lead to medication errors (e.g., same cap colors). When problems are recognized, consider purchasing the product from a different manufacturer. Communicate with staff when a new product is available and review the packaging, storage location (e.g., any medication trays, automated dispensing cabinets), and other pertinent information. ISMP [Targeted Medication Safety Best Practices for Hospitals](#), *Best Practice 18*, calls for maximizing the use of barcode verification prior to medication administration by expanding use, including in perioperative areas.



Remembering Dr. Lucian Leape. We were saddened to learn of the passing of our friend, Dr. Lucian L. Leape, on June 30, 2025. Dr. Leape was a former pediatric surgeon and researcher whose contributions in the 1990s laid the groundwork for the patient safety movement. After witnessing recurring medical errors that resulted in

continued on page 3 — **SAFETYwires** >

> **Counterfeit drugs** — continued from page 2

- Filter needles were not provided for use with the glass ampule
- There was no NDC or drug identification number
- The carton stated the drug should be refrigerated, but did not come packaged with cold packs; also, semaglutide should not be frozen but the carton stated, “Store frozen at -25°C to -15°C (-13°F to 5°F) for long-term storage”
- An unapproved route of administration (intramuscular) was included on the carton label
- There was no beyond-use date (BUD) provided for the reconstituted product

Recommendations

Healthcare organizations have a crucial role in raising awareness about the threat of SF drugs to patients. Share this case with your medication safety committee and clinical teams that care for patients in the outpatient, urgent care, and emergency settings. Provide widespread education to practitioners that about **95% of so-called online pharmacies operate illegally**.¹ Leaders must stay informed about medication-related incidents shared by safety organizations and develop mitigation strategies for known problem drugs, including glucagon-like peptide-1 (GLP-1) agonists. Monitor patients for unexpected outcomes (e.g., increased side effects) and consider if SF medications could be the culprit. When reviewing a patient’s medication history, include a scripted open-ended question asking where they obtain their medications.

Share with patients the warning signs that may indicate a pharmacy could be selling SF drugs. Refer them to resources such as the US Food and Drug Administration’s (FDA) [BeSafeRx campaign](#). Educate patients about the National Association of Boards of Pharmacy’s (NABP) [searchable list of accredited digital pharmacies](#) that comply with quality assurance criteria. Encourage patients to check for a licensed pharmacist’s availability at any online pharmacy they are considering, which can help determine the pharmacy’s legitimacy. Inform patients that when a pharmacy does not require a provider’s prescription to dispense a prescription medication, the facility is likely illegal and unsafe.

Ask patients to review medication packages and labels for **spelling errors**, which is one of the **most noticeable mistakes** on SF products.² Ensure the drug comes with patient-specific dosing instructions and information about how to prepare and administer the dose. Patients should be suspicious if vials are not labeled, if they are not provided with an appropriate measuring device, or if the drug is not shipped according to the storage requirements on the label (e.g., states to refrigerate but does not arrive with cold packs). Stress to patients that if anything does not look right, they should check with a healthcare practitioner before taking the medication.

References

- 1) Brady J, Baney L. [Congress holds registries and registrars accountable for rogue online pharmacies](#). National Association of Boards of Pharmacy (NABP). January 21, 2022. Accessed April 2, 2025.
- 2) [How to identify fake medicines](#). Pfizer. Accessed April 2, 2025.

To subscribe: www.ismp.org/ext/1368

ISMP Nurse AdviseERR (ISSN 1550-6304) © 2025 Institute for Safe Medication Practices (ISMP). All rights reserved. Redistribution and reproduction of this newsletter, including posting on a public-access website, beyond the terms of agreement of your subscription, is prohibited without written permission from ISMP. This is a peer-reviewed publication.

Report medication and vaccine errors to ISMP: Please visit: www.ismp.org/report-medication-error or call 1-800-FAIL-SAFE. ISMP guarantees the confidentiality of information received and respects the reporters’ wishes regarding the level of detail included in publications.

Editors: Ann Shastay, MSN, RN, AOCN; Shannon Bertagnoli, PharmD; Jana O’Hara, MSN, RN, CPHQ, CPPS. ISMP, 3959 Welsh Road, #364, Willow Grove, PA 19090. Email: ismpinfo@ismp.org; Tel: 215-947-7797.

> **SAFETY wires** continued from page 2

significant patient harm and death, Dr. Leape left his surgical practice to collaborate with colleagues on what became known as the Harvard Medical Practice Study, which chronicled for the first time the number of injuries and deaths that resulted from medical error.

Dr. Leape, along with Dr. David Bates, were the recipients of an ISMP **Cheers Award** in 1999 for their medication safety research, including their published work on the impact of intensive care unit-based clinical pharmacists reducing adverse drug events. Dr. Leape was also the inaugural recipient of the ISMP **Lifetime Achievement Award** in 2001. He was honored for publication of the Harvard Medical Practice Study, which led to the landmark report, “To Err Is Human: Building a Safer Health System,” published in 1999 by the Institute of Medicine (now the National Academy of Medicine). Through this work, Dr. Leape and colleagues exposed a new culprit in “adverse events”—the system. He immediately became a champion of the “medical error movement” and became a leading advocate of the non-punitive, systems approach to error prevention.

Dr. Leape often included ISMP in discussions on how to improve patient safety. He worked closely with us to develop **ISMP’s Hierarchy of Effectiveness of Risk Reduction Strategies**. We are keenly aware of the pivotal role he played in making ISMP what it is today—we would not be the same organization without him. Most of all, Dr. Leape’s research will forever be his legacy, as he helped in ways that saved thousands of lives from medical errors and harm. Healthcare practitioners worldwide will be forever grateful for his work and dedication. We will greatly miss Dr. Lucian Leape and offer our deepest condolences to his family.

Just Culture Scholarship

Applications are now being accepted for the **Judy Smetzer Just Culture Champion Scholarships**. For more information and to submit an application, click [here](#). The deadline to apply is **September 30, 2025**.